ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model (Q90239928)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

title

ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

author name string

Sargur Madabushi Srideshikan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Jamison Brooks

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Darren Zuro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Bijender Kumar

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

James Sanchez

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Liliana Echavarria Parra

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Marvin Orellana

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Paresh Vishwasrao

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Indu Nair

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Junie Chea

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Kofi Poku

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Nicole Bowles

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Todd Ebner

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Justin Molnar

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Joseph Rosenthal

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Daniel A Vallera

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Jeffrey Y C Wong

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Anthony S Stein

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

David Colcher

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

John E Shively

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Paul J Yazaki

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Susanta K Hui

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

publication date

23 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

published in

Clinical Cancer Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

issue

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

page(s)

7463-7474

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31548348%20AND%20SRC:MED&resulttype=core&format=json

The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia

12 April 2020

cites work

1 reference

12 December 2020

Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies

1 reference

12 December 2020

Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model

1 reference

12 December 2020

Chimeric and humanized antibodies with specificity for the CD33 antigen

1 reference

12 December 2020

A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity

1 reference

12 December 2020

Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias

1 reference

12 December 2020

Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia

1 reference

12 December 2020

Parametric images of antibody pharmacokinetics in Bi213-HuM195 therapy of leukemia

1 reference

12 December 2020

Targeted alpha particle immunotherapy for myeloid leukemia

1 reference

12 December 2020

Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias

1 reference

12 December 2020

Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia

1 reference

12 December 2020

CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

1 reference

12 December 2020

The promise of immuno-PET in radioimmunotherapy

1 reference

12 December 2020

Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells

1 reference

12 December 2020

ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2

1 reference

12 December 2020

Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region.

1 reference

12 December 2020

Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease

1 reference

12 December 2020

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

12 December 2020

False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma

1 reference

12 December 2020

Early assessment of treatment response in patients with AML using [18F]FLT PET imaging

1 reference

12 December 2020

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia

1 reference

12 December 2020

Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia

1 reference

12 December 2020

¹⁸F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia

1 reference

12 December 2020

High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation

1 reference

12 December 2020

Causes and imaging features of false positives and false negatives on F-PET/CT in oncologic imaging

1 reference

12 December 2020

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

1 reference

12 December 2020

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

1 reference

12 December 2020

Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology

1 reference

12 December 2020

Extramedullary disease in patients with acute myeloid leukemia assessed by 18F-FDG PET

1 reference

12 December 2020

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

1 reference

12 December 2020

Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study

1 reference

12 December 2020

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.

1 reference

12 December 2020

Antibody therapy for acute myeloid leukaemia.

1 reference

12 December 2020

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

1 reference

12 December 2020

Increased bone marrow uptake of 18F-FDG in leukemia patients: preliminary findings

1 reference

12 December 2020

Practical Immuno-PET Radiotracer Design Considerations for Human Immune Checkpoint Imaging.

1 reference

12 December 2020

Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia

1 reference

12 December 2020

CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy

1 reference

12 December 2020

Genetic and epigenetic heterogeneity and the impact on cancer relapse

1 reference

12 December 2020

Early assessment of response to induction therapy in acute myeloid leukemia using 18F-FLT PET/CT

1 reference

12 December 2020

Whole-Body Distribution of Leukemia and Functional Total Marrow Irradiation Based on FLT-PET and Dual-Energy CT.

1 reference

12 December 2020

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

1 reference

12 December 2020

Copper-64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma

1 reference

12 December 2020

Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia.

1 reference

12 December 2020

Investigational CD33-targeted therapeutics for acute myeloid leukemia.

1 reference

12 December 2020